R
REVOLUTION MEDICINES INC
NASDAQ: RVMD (Revolution Medicines, Inc.)
Kemas kini terakhir: 8 jam lalu162.99
5.22 (3.31%)
| Penutupan Terdahulu | 157.77 |
| Buka | 160.94 |
| Jumlah Dagangan | 4,702,503 |
| Purata Dagangan (3B) | 3,150,120 |
| Modal Pasaran | 34,651,099,136 |
| Harga / Jualan (P/S) | 9.04 |
| Harga / Buku (P/B) | 23.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| EPS Cair (TTM) | -4.01 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.46% |
| Nisbah Semasa (MRQ) | 13.46 |
| Aliran Tunai Operasi (OCF TTM) | -591.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -349.13 M |
| Pulangan Atas Aset (ROA TTM) | -23.09% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Revolution Medicines, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.80 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.02% |
| % Dimiliki oleh Institusi | 105.87% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ANDERS JACK | - | 156.58 | -2,722 | -426,211 |
| CISLINI JEFF | - | 156.58 | -2,157 | -337,743 |
| GOLDSMITH MARK A | - | 156.58 | -10,020 | -1,568,932 |
| HORN MARGARET A | - | 155.69 | -100,000 | -15,829,916 |
| KELSEY STEPHEN MICHAEL | - | 156.58 | -4,175 | -653,722 |
| MANCINI ANTHONY | - | 156.58 | -4,615 | -722,617 |
| Jumlah Keseluruhan Kuantiti Bersih | -123,689 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -19,539,140 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 156.25 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HORN MARGARET A | Pegawai | 17 Jun 2026 | Jual automatik (-) | 29,600 | 157.77 | 4,669,992 |
| HORN MARGARET A | Pegawai | 17 Jun 2026 | Pelaksanaan pilihan | 29,600 | - | - |
| KELSEY STEPHEN MICHAEL | Pegawai | 16 Jun 2026 | Jual automatik (-) | 4,175 | 156.58 | 653,722 |
| ANDERS JACK | Pegawai | 16 Jun 2026 | Jual automatik (-) | 2,722 | 156.58 | 426,211 |
| CISLINI JEFF | Pegawai | 16 Jun 2026 | Jual automatik (-) | 2,157 | 156.58 | 337,743 |
| GOLDSMITH MARK A | Pegawai | 16 Jun 2026 | Jual automatik (-) | 10,020 | 156.58 | 1,568,932 |
| MANCINI ANTHONY | Pegawai | 16 Jun 2026 | Jual (-) | 4,615 | 156.58 | 722,617 |
| HORN MARGARET A | Pegawai | 15 Jun 2026 | Jual automatik (-) | 60,400 | 160.06 | 9,667,624 |
| HORN MARGARET A | Pegawai | 15 Jun 2026 | Pelaksanaan pilihan | 60,400 | - | - |
| HORN MARGARET A | Pegawai | 11 Jun 2026 | Pelaksanaan pilihan | 10,000 | - | - |
| HORN MARGARET A | Pegawai | 11 Jun 2026 | Jual automatik (-) | 10,000 | 149.23 | 1,492,300 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Apr 2026 | CNBC | Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |